Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab-nivolumab versus regorafenib or TAS-102 in later-line MSS metastatic colorectal cancer
NL-OMON53835Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of relatlimab, nivolumab, regorafenib, trifluridine and tipiracil in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall survival in randomized participants with PD-L1 CPS >= 1 and Overall survival in all randomized participants. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON53835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53835.